LifeMD is one of the independent pure-play telehealth platforms most exposed to the GLP-1 commercial story, alongside Hims & Hers, Ro, and Eucalyptus. The company has built a meaningful share of US oral GLP-1 distribution by routing patients through state-by-state pharmacy networks.
Key 2026 data points covered on this site: LifeMD's new-patient volume jumped from 300–400 per day before the January 5 Wegovy pill launch to 600–1,000 per day after — credited by CNBC's May 6 piece to the pill format and improved insurance coverage unlocking GLP-1-curious patients. Amazon One Medical's $25/month GLP-1 program (covered April 21–22) raised competitive pressure on the independent telehealth platforms, briefly pushing Hims & Hers down 6% intraday in late April.
Stories here cover patient-volume metrics, payer dynamics, and the broader telehealth peptide ecosystem. See #telehealth, #hims-hers, and #wegovy-pill.
Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.
CNBC's May 6 Wegovy-Q1 piece documented LifeMD new-patient volume jumping from 300–400 per day before the Wegovy pill January 5 launch to 600–1,000 per day after, with the telehealth platform crediting the pill format and improved insurance coverage for unlocking a wave of GLP-1-curious patients who had not previously committed to injectables. LifeMD has been one of the most exposed independent pure-play telehealth obesity platforms during the Novo channel-expansion era, and its data point feeds the broader 'oral GLP-1 expands the market' thesis that Lilly's Foundayo team also referenced on the April 30 Q1 call (where 80% of Foundayo patients were new to the GLP-1 class).
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.